Status evaluation of HER2/Neu receptors in breast cancers

Adeel Munawar, Bani Abid, Mahmooda Tasneem


Objective: The main aim of this study was to evaluate the status of HER2/Neu receptors in patients with breast cancer.

Type of study: It is a cross sectional study.

Place and Duration of study: This study was carried out in a duration of 9 months from February 2018 to October 2018 in surgical department of Sir Ganga Ram Hospital Lahore.

Materials and Methods: A total of 100 patients were included in this study which presented in outdoor department of surgery. Female patients who had been diagnosed with breast cancer and were between the ages of 20 to 65 years were included in this study. Only those patients were included who had ductal / lobular carcinoma. Those patients in which there was a recurrence of breast cancer were excluded from this study and others excluded were the ones who rejected histopathology. Informed consent was taken from all the patients or their relatives. Ethical committee approval was taken. A pre-designed proforma was used to collect the data of the patients. Samples which were taken were sent to a reliable laboratory for HER2 / Neu status, tumor staging, histopathological type and progesterone and estrogen status. After tissue biopsy immunohistochemical studies were done and Hercep test was used to analysis. 3 plus score were considered positive and less than 3 were negative. SPSS version 16 was used for data analysis.

Results: A total of 100 patients were selected for the study. The mean age of the patients was 43.88 years. Positive and negative HER2/Neu receptors were seen in 40% and 60% of the patients respectively. 21% of the patients were diagnosed with grade 1 tumor, 35 patients had grade 2 tumor followed by 44% of the patients with grade 3 tumor. Ductal carcinoma and lobular carcinoma were found to be 87% and 13% respectively. Estrogen receptor(ER) was found to be positive in 75% of the patients while 25% of the patients had negative ER receptors. Progesterone (PR) receptors were found to be negative in 35% of the patients while 65% of the patients were positive for PR receptors.

Conclusion: Higher incidence of HER2/Neu receptors over expression is seen in this study. Patients with grade 3 tumors had the highest incidence. PR and ER were positive in most of the cases and HER2 /Neu receptors had no relation with obesity or age.


Breast carcinoma, ER/PR, HER2/Neu receptors, over expression.

Full Text:



Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad. 2008 Sep;20(3):23–6.

Dutta V, Chopra G, Sahai K, Nema S. Hormone receptors, Her-2/neu and chromosomal aberrations in breast cancer. Med J Armed Forces India. 2008 Jan;64(1):11–5.

Brunicardi FC. Schwartz's principles of surgery. 9th ed. USA. Mcgraw Hill; 2010

Naqvi SQH, Naqvi A, Anwar M, Khan MS, Akhund AA. Significance of HER-2/neuOncoprotein overexpression in invasive ductal breast cancer. Ann AbbasiShaheedHosp Karachi Med Dent Coll 2007;12:79–83.

Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, et al. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int J Cancer. 2007 Sep 1;121(5):1079–85.

Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193–201.

Panjwani P, Epari S, Karpate A, Shirsat H, Rajsekharan P, Basak R, et al. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: experience of a tertiary cancer referral centre in India. Indian J Med Res. 2010 Sep;132:287–94.

Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer - the present. Histopathology 2008;52:82-90.

Walker RA. Use and assessment of diagnostic and predictive markers in breast pathology. Current Diagnostic Pathology. 2007 Apr;13(2):126–34.

Nida Iqbal and Naveed Iqbal, “Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications,” Molecular Biology International, vol. 2014, Article ID 852748, 9 pages, 2014. doi:10.1155/2014/852748

Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. ExpMolPathol. 2009 Aug;87(1):1–11.

Favret AM, et al: Locally advanced breast cancer: Is surgery necessary? Breast J 7:131, 2001. [PMID: 11328324]

Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad. 2008 Sep;20(3):23–6.

Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer. 2010 Mar;47(1):16–22.

Alahwal MS. HER-2 positivity and correlations with other histopathologic features in Breast Cancer patients–hospital basd study. J Pak Med Assoc 2006;56: 65–8.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. correlation of HER-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11:278–80.

Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbass F. Significance of HER-2/neuOncoprotein Overexpression on node positive invasive breast cancer. J CollPhysSurg Pak 2002;12:534–7.

Mostafa M, larsen M, and loveR.Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. J Bangladesh CollPhys Surg. 2010; 28(3): 157–162.

Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE. Locally advanced breast cancer: is surgery necessary? Breast J. 2001 Apr;7(2):131–7.

Shet T, Agrawal A, Nadkarni M, et al (2009). Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol,52,171-4.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.